These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23684887)

  • 21. KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis.
    Yi EY; Park SY; Song HS; Son MJ; Yi KY; Yoo SE; Kim YJ
    Exp Mol Med; 2006 Oct; 38(5):502-8. PubMed ID: 17079866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis.
    Lin KT; Lien JC; Chung CH; Kuo SC; Huang TF
    Eur J Pharmacol; 2010 Mar; 630(1-3):53-60. PubMed ID: 20067787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
    Morais C; Gobe G; Johnson DW; Healy H
    Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
    MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis.
    Pourgholami MH; Khachigian LM; Fahmy RG; Badar S; Wang L; Chu SW; Morris DL
    Biochem Biophys Res Commun; 2010 Jul; 397(4):729-34. PubMed ID: 20537982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-angiogenic effect of quercetin and its 8-methyl pentamethyl ether derivative in human microvascular endothelial cells.
    Lupo G; Cambria MT; Olivieri M; Rocco C; Caporarello N; Longo A; Zanghì G; Salmeri M; Foti MC; Anfuso CD
    J Cell Mol Med; 2019 Oct; 23(10):6565-6577. PubMed ID: 31369203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. γ-Tocotrienol inhibits angiogenesis of human umbilical vein endothelial cell induced by cancer cell.
    Li Y; Sun WG; Liu HK; Qi GY; Wang Q; Sun XR; Chen BQ; Liu JR
    J Nutr Biochem; 2011 Dec; 22(12):1127-36. PubMed ID: 21292465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase.
    Son SH; Kim MJ; Chung WY; Son JA; Kim YS; Kim YC; Kang SS; Lee SK; Park KK
    Cancer Lett; 2009 Jul; 280(1):86-92. PubMed ID: 19307054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo.
    Saraswati S; Agrawal SS
    Cancer Lett; 2013 May; 332(1):83-93. PubMed ID: 23348691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
    Gilbert RE; Vranes D; Berka JL; Kelly DJ; Cox A; Wu LL; Stacker SA; Cooper ME
    Lab Invest; 1998 Aug; 78(8):1017-27. PubMed ID: 9714188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy.
    Rezzola S; Nawaz IM; Cancarini A; Ravelli C; Calza S; Semeraro F; Presta M
    Angiogenesis; 2017 Nov; 20(4):629-640. PubMed ID: 28905243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling.
    De Luisi A; Mangialardi G; Ria R; Acuto G; Ribatti D; Vacca A
    Eur Respir J; 2009 Oct; 34(4):958-66. PubMed ID: 19357149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.
    Witmer AN; Blaauwgeers HG; Weich HA; Alitalo K; Vrensen GF; Schlingemann RO
    Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):849-57. PubMed ID: 11867607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.
    Sennlaub F; Valamanesh F; Vazquez-Tello A; El-Asrar AM; Checchin D; Brault S; Gobeil F; Beauchamp MH; Mwaikambo B; Courtois Y; Geboes K; Varma DR; Lachapelle P; Ong H; Behar-Cohen F; Chemtob S
    Circulation; 2003 Jul; 108(2):198-204. PubMed ID: 12821538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
    Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.